Abstracts tagged "anti-TNF therapy and Clinical Response"

Abstract Number: 1088 • 2019 ACR/ARP Annual Meeting
Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg ¹, Lennart Jacobsson ², Michael J. Nissen ³, Eirik Kristianslund ⁴, Herman Mann ⁵, Maria José Santos ⁶, Manuel Pombo-Suarez ⁷, Dan Nordström ⁸, Ziga Rotar ⁹, Bjorn Gudbjornsson ¹⁰, Fatos Onen ¹¹, Catalin Codreanu ¹², Anne Gitte Loft ¹³, Ulf Lindström ¹⁴, Burkhard Moeller ¹⁵, Joe Sexton ¹⁶, Karel Pavelka ⁵, Anabela Barcelos ¹⁷, Carlos Sánchez-Piedra ¹⁸, Kari K. Eklund ¹⁹, Matija Tomsic ²⁰, Thorvardur J Love ²¹, Gercek Can ²², Ruxandra IONESCU ²³, Marleen van de Sande ²⁴, Irene van der Horst-Bruinsma ²⁵, Gareth Jones ²⁶, Florenzo Iannone ²⁷, Brigitte Michelsen ¹, Lise Hyldstrup ²⁸, Niels Steen Krogh ²⁹, Mikkel Østergaard ³⁰ and Merete Lund Hetland ³¹, ¹EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ²Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ³University Hospital Geneva, Geneva, Switzerland, ⁴Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁷Rheumatology Unit, Clinical University Hospital of Santiago de Compostela,, Santiago, Spain, ⁸Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹⁰Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹¹Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ¹⁴University of Gothenburg, Gothenburg, Sweden, ¹⁵University Hospital Bern, Bern, Switzerland, ¹⁶Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁷Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ¹⁸Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁹ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ²⁰Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²²TURKBIO Registry and Division of Rheumatology, School of Medicine Dokuz Eylul University,, Izmir, Turkey, ²³SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁴Amsterdam UMC, Amsterdam, Netherlands, ²⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁶University of Aberdeen, Aberdeen, United Kingdom, ²⁷Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁹Zitelab / DANBIO, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with psoriatic arthritis (PsA), but some patients switch to a different TNFi because of adverse…
Abstract Number: 1551 • 2019 ACR/ARP Annual Meeting
Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration
Lykke Midtbøll Ørnbjerg ¹, Cecilie Heegaard Brahe¹, Anne Gitte Loft ², Johan Askling ³, Adrian Ciurea ⁴, Herman Mann ⁵, Servet Akar ⁶, Eirik Kristianslund ⁷, Dan Nordström ⁸, Maria José Santos ⁹, Catalin Codreanu ¹⁰, Manuel Pombo-Suarez ¹¹, Ziga Rotar ¹², Bjorn Gudbjornsson ¹³, Daniela DiGuiseppe ¹⁴, Michael J. Nissen ¹⁵, Karel Pavelka ⁵, Soner Senel ¹⁶, Joe Sexton ¹⁷, Kari K. Eklund ¹⁸, Anabela Barcelos ¹⁹, Ruxandra IONESCU ²⁰, Carlos Sánchez-Piedra ²¹, Matija Tomsic ²², Arni Jon Geirsson ²³, Irene van der Horst-Bruinsma ²⁴, Gary Macfarlane ²⁵, Florenzo Iannone ²⁶, Brigitte Michelsen ¹, Lise Hyldstrup ²⁷, Niels Steen Krogh ²⁸, Merete Lund Hetland ²⁹ and Mikkel Østergaard ³⁰, ¹EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ³Karolinska Institutet, Stockholm, Sweden, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ⁷Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ⁸Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹¹Rheumatology Unit, Clinical University Hospital of Santiago de Compostela,, Santiago, Spain, ¹²UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹³Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁴Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, ¹⁵University Hospital Geneva, Geneva, Switzerland, ¹⁶Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, ¹⁷Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁸ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ¹⁹Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ²⁰SPITALUL CLINIC SFANTA MARIA, Bucharest, ²¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²²Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁵University of Aberdeen, Aberdeen, United Kingdom, ²⁶Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁸Zitelab / DANBIO, Copenhagen, Denmark, ²⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with axial spondyloarthritis (axSpA), but still some patients switch to a different TNFi because of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].